Versanis Bio

Versanis Bio Aims to Develop a New Therapy for Metabolic Diseases and Obesity. The company is advancing bimagrumab, a human monoclonal antibody targeting the activin type II receptor, which blocks the binding of ligands including activin A and myostatin.